← All Humacyte, INC filings

Humacyte, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
HUMA
Humacyte, INC
10-K: Humacyte Launches Symvess, Faces Going Concern Doubt
Humacyte, Inc. commenced U.S. commercial sales of its FDA-approved Symvess for vascular trauma in Q1 2025, generating $1.4 million in revenue, but faces substantial doubt about its ability to continue as a going concern.
NASDAQ
HUMA
Humacyte, INC
10-K: Humacyte Secures FDA Approval for Symvess Vascular Graft, Commences U.S. Commercial Launch Amidst Ongoing Clinical Development and Financing Activities
Humacyte, Inc. announced FDA approval for its bioengineered tissue product Symvess for extremity vascular trauma and initiated its U.S. commercial launch in Q1 2025, while continuing Phase 3 trials for other indications and securing significant financing.
NASDAQ
HUMA
Humacyte, INC
10-K: Humacyte Details Capital Structure and Warrant Terms in 10-K Filing
Humacyte's 10-K filing provides a detailed description of its capital stock, including common and preferred shares, as well as the terms of outstanding warrants.